Our top pick for
ChemoCentryx, Inc is a biotechnology business based in the US. ChemoCentryx shares (CCXI) are listed on the NASDAQ and all prices are listed in US Dollars. ChemoCentryx employs 82 staff and has a trailing 12-month revenue of around USD$70.6 million.
|52-week range||USD$30.72 - USD$70.29|
|50-day moving average||USD$62.0212|
|200-day moving average||USD$57.0653|
|Wall St. target price||USD$82.38|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.923|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$70.6 million|
|Gross profit TTM||USD$-34,148,000|
|Return on assets TTM||-7%|
|Return on equity TTM||-17.57%|
|Market capitalisation||USD$4.6 billion|
TTM: trailing 12 months
There are currently 4.7 million ChemoCentryx shares held short by investors – that's known as ChemoCentryx's "short interest". This figure is 1.7% down from 4.8 million last month.
There are a few different ways that this level of interest in shorting ChemoCentryx shares can be evaluated.
ChemoCentryx's "short interest ratio" (SIR) is the quantity of ChemoCentryx shares currently shorted divided by the average quantity of ChemoCentryx shares traded daily (recently around 529248.92897407). ChemoCentryx's SIR currently stands at 8.87. In other words for every 100,000 ChemoCentryx shares traded daily on the market, roughly 8870 shares are currently held short.
However ChemoCentryx's short interest can also be evaluated against the total number of ChemoCentryx shares, or, against the total number of tradable ChemoCentryx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ChemoCentryx's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 ChemoCentryx shares in existence, roughly 70 shares are currently held short) or 0.1005% of the tradable shares (for every 100,000 tradable ChemoCentryx shares, roughly 101 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against ChemoCentryx.
Find out more about how you can short ChemoCentryx stock.
We're not expecting ChemoCentryx to pay a dividend over the next 12 months.
Over the last 12 months, ChemoCentryx's shares have ranged in value from as little as $30.72 up to $70.29. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ChemoCentryx's is 1.3906. This would suggest that ChemoCentryx's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.